Publications by authors named "C Juhls"
Background: Deoxyribonucleic acid (DNA) vaccines are used for experimental immunotherapy of equine melanoma. The injection of complexed linear DNA encoding interleukin (IL)-12/IL-18 induced partial tumour remission in a clinical study including 27 grey horses. To date, the detailed mechanism of the anti-tumour effect of this treatment is unknown.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated DNA vaccination as a potential treatment for equine melanoma in grey horses, utilizing three different vaccine combinations administered over a period of 120 days.
- The results showed a significant reduction in tumor volume across all groups, with a decrease to 79.1% by day 120, although the specific vaccine components did not influence these outcomes.
- Additionally, no immune response to the targeted proteins was observed, although an increase in body temperature was noted in horses the day after vaccination.
Article Synopsis
- Combination therapies for leishmaniasis aim to reduce treatment duration and enhance outcomes for the disease's complex forms.
- Researchers tested a new DNA vaccine (LEISHDNAVAX) alongside standard antileishmanial medication in cases of visceral leishmaniasis.
- Results demonstrated that the vaccine improves the effectiveness of a lower dose of liposomal amphotericin B in mouse models.
Background: Equine melanoma has a high incidence in grey horses. Xenogenic DNA vaccination may represent a promising therapeutic approach against equine melanoma as it successfully induced an immunological response in other species suffering from melanoma and in healthy horses. In a clinical study, twenty-seven, grey, melanoma-bearing, horses were assigned to three groups (n = 9) and vaccinated on days 1, 22, and 78 with DNA vectors encoding for equine (eq) IL-12 and IL-18 alone or in combination with either human glycoprotein (hgp) 100 or human tyrosinase (htyr).
View Article and Find Full Text PDFThe leishmaniases are a complex of vector-borne diseases caused by protozoan parasites of the genus Leishmania. LEISHDNAVAX is a multi-antigen, T-cell epitope-enriched DNA vaccine candidate against human leishmaniasis. The vaccine candidate has been proven immunogenic and showed prophylactic efficacy in preclinical studies.
View Article and Find Full Text PDF